BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:21 PM
May 07, 2009
 |  BC Extra  |  Company News

NICE rebuffs Nexavar in HCC

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Nexavar sorafenib from Bayer AG (Xetra:BAY) to treat advanced hepatocellular carcinoma (HCC) in patients for...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >